In collaboration with Abound Bio, the MPA technology has been used to identify a monoclonal antibody that targets and neutralizes SARS-CoV-2. The antibody did not display any off-target binding on the MPA and has been selected for further development.

Nearly 25% of preclinical antibodies have off-target binding to unintended protein targets, which can lead to adverse effects in patients. The company's MPA provides specificity results in less than a month, which is faster than other traditional preclinical safety experiments, according to the company.

The MPA is a collection of 6,000 membrane proteins expressed in live cells, representing nearly the entire human membrane proteome. Integral has also launched an antibody neutralization test using pseudotyped SARS-CoV-2 reporter viruses.

Integral Molecular wins COVID-19 NIAID award
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics...